The U.S. Food and Drug Administration has once again declined to approve Aldeyra Therapeutics treatment for dry eye disease, ...

NEW YORK CITY, NY / ACCESS Newswire / March 31, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Bausch + Lomb shares tumbled in intraday trading Friday, a day after the eye-care company announced a "voluntary recall" of ...

Bausch + Lomb (NYSE:BLCO) stock falls as the company's voluntary recall of enVista lenses leads to a downgrade at Wells Fargo ...

Bausch + Lomb said on Thursday it will recall some of its implantable eye lenses after receiving reports of complications, ...

NEW YORK CITY, NY / ACCESS Newswire / March 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

J.P. Morgan analysts said it was too early to discuss the financial impact of the recall, but estimated that $70 million to ...

Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 10.6% in the afternoon session after the company announced the ...

Miebo produced substantial symptom relief in patients with dry eye disease during the first day and succeeding weeks of ...

Bronstein, Gewirtz & Grossman, LLC is currently investigating potential claims on behalf of purchasers of Bausch + Lomb (NYSE ...

Bausch + Lomb has voluntarily recalled IOLs included on its enVista platform, including enVista Aspire, enVista Envy and ...

Detailed price information for Bausch Lomb Corporation (BLCO-T) from The Globe and Mail including charting and trades.